ArriVent BioPharma Faces Legal Probe After Phase 3 Trial Failure and 56.7% Stock Plunge

Key Facts

1ArriVent BioPharma announced that its Phase 3 FURVENT trial of firmonertinib did not meet its primary endpoint.

2Law firm Levi & Korsinsky initiated an investigation on behalf of shareholders after AVBP stock plunged 56.7% in premarket trading.

ArriVent BioPharma announced that its Phase 3 FURVENT trial of firmonertinib did not meet its primary endpoint. According to a report from PR Newswire, the law firm Levi & Korsinsky initiated an investigation on behalf of shareholders after AVBP stock plunged 56.7% in premarket trading on October 6, 2026.

AVBP closed at $28.46 on October 5, 2026, prior to the clinical update that triggered the massive sell-off. The legal probe is examining whether the company made materially false or misleading statements regarding the trial's prospects, following a $250 million stock offering conducted earlier in 2026.